BioWorld

Ani buying Egetis for newly approved rare disease drug Emcitate

Five weeks after winning U.S. FDA approval of Emcitate (tiratricol) to treat peripheral thyrotoxicosis in those with MCT8 ...
BioWorld

T-Therapeutics raises $133M for TCR bispecifics in cancer, autoimmune

T-Therapeutics Ltd. has raised $133 million in an oversubscribed series B, providing the means to deliver clinical proof of concept for its T-cell receptor-CD3 bispecifics in solid tumors and ...
BioWorld

Abbvie bets $1.47B-plus on Nxera’s EP4 agonist

Abbvie Inc. is paying Nxera Pharma Co. Ltd. $100 million up front for worldwide rights to NXE-0033744, a phase II-ready oral EP4 receptor agonist designed to act locally in the gastrointestinal tract ...
BioWorld

Alethio raises £67M series A for mutation-agnostic platelet disorder therapy

Alethio Therapeutics Ltd. has closed a £67 million (US$90.3 million) series A round that with a fair wind will see its lead ...